Bone Marrow-Derived Mesenchymal Stem Cells Modified with Akt1 Ameliorates Acute Liver GVHD.
MouseChemical/toxinBALB/c (H2d) recipients; bone marrow mesenchymal stem cell donors C57BL/6Femalen = 30 mice in total, 10 per group across three groupsIntravenous, via the tail vein30 minutes after concanavalin A administration
Model: Concanavalin A-induced immune-mediated acute liver injury (20 mg/kg concanavalin A intravenously) used as a model of acute liver graft-versus-host disease
AKT1-modified mesenchymal stem cells outperformed unmodified cells, giving larger reductions in serum ALT and AST, less hepatic necrosis, lower TNF-alpha and IFN-gamma, and better cell homing and survival in the injured liver.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.